Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).
Fernando Rivera
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Lee Steven Schwartzberg
Consultant or Advisory Role - Amgen
Meinolf Karthaus
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Other Remuneration - Amgen; Roche
Gianpiero Fasola
Consultant or Advisory Role - Amgen
Jean-Luc Canon
Consultant or Advisory Role - Amgen
J. Randolph Hecht
Consultant or Advisory Role - Amgen
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly Smith Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen